The DSMB allowing us to move forward as expected. The meeting was Monday and a decision on Tuesday, this was a peak at safety not an evaluation of 30,000 data points. It's safe and we get to proceed as planned.
Is it possible the FDA realizes the importance of the trial and the future of Leronlimab? Maybe that is why this is being done "by the book". Won't an approval here increase our chances of approvals for future indications like HIV, where we know it works? How do they approve for COVID and not for HIV?
Just my thought.
This board is a wealth of knowledge and opinions...Thank you.